ProfileGDS5678 / 1443806_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 48% 47% 47% 45% 46% 48% 47% 46% 45% 46% 47% 45% 47% 47% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.1799648
GSM967853U87-EV human glioblastoma xenograft - Control 23.0933847
GSM967854U87-EV human glioblastoma xenograft - Control 33.0969347
GSM967855U87-EV human glioblastoma xenograft - Control 42.9947345
GSM967856U87-EV human glioblastoma xenograft - Control 53.0311946
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.2463648
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1861247
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.0637946
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.0333445
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0515846
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0904247
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.0284445
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.109647
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.090147